Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1

• Published in: PLoS medicine 2004-10, Vol.1 (1), p.e19-e19
• Main Authors: van Leth, Frank, Phanuphak, Prahpan, Stroes, Erik, Gazzard, Brian, Cahn, Pedro, Raffi, François, Wood, Robin, Bloch, Mark, Katlama, Christine, Kastelein, John J P, Schechter, Mauro, Murphy, Robert L, Horban, Andrzej, Hall, David B, Lange, Joep M A, Reiss, Peter
• Format: Article
• Language: English
• Subjects: Adult; Anti-HIV Agents - pharmacology; Anti-HIV Agents - therapeutic use; Benzoxazines; Cardiology/Cardiac Surgery; Cardiovascular disease; Cardiovascular Medicine; Cholesterol; Cholesterol, HDL - blood; Cholesterol, HDL - drug effects; Clinical trials; Drug therapy; Drugs and adverse drug reactions; Female; High density lipoprotein; HIV Infection/AIDS; HIV Infections - drug therapy; HIV-1 - pathogenicity; HIV/AIDS; Humans; Infections; Lipids; Lipoproteins; Male; Middle Aged; Nevirapine - pharmacology; Nevirapine - therapeutic use; Oxazines - pharmacology; Oxazines - therapeutic use; Pharmaceuticals; Plasma; Triglycerides
• ISSN: 1549-1676; 1549-1277; 1549-1676
• DOI: 10.1371/journal.pmed.0010019

Patients infected with HIV-1 initiating antiretroviral therapy (ART) containing a non-nucleoside reverse transcriptase inhibitor (NNRTI) show presumably fewer atherogenic lipid changes than those initiating most ARTs containing a protease inhibitor. We analysed whether lipid changes differed between the two most commonly used NNRTIs, nevirapine (NVP) and efavirenz (EFV). Prospective analysis of lipids and lipoproteins was performed in patients enrolled in the NVP and EFV treatment groups of the 2NN study who remained on allocated treatment during 48 wk of follow-up. Patients were allocated to NVP (n = 417), or EFV (n = 289) in combination with stavudine and lamivudine. The primary endpoint was percentage change over 48 wk in high-density lipoprotein cholesterol (HDL-c), total cholesterol (TC), TC:HDL-c ratio, non-HDL-c, low-density lipoprotein cholesterol, and triglycerides. The increase of HDL-c was significantly larger for patients receiving NVP (42.5%) than for patients receiving EFV (33.7%; p = 0.036), while the increase in TC was lower (26.9% and 31.1%, respectively; p = 0.073), resulting in a decrease of the TC:HDL-c ratio for patients receiving NVP (-4.1%) and an increase for patients receiving EFV (+5.9%; p < 0.001). The increase of non-HDL-c was smaller for patients receiving NVP (24.7%) than for patients receiving EFV (33.6%; p = 0.007), as were the increases of triglycerides (20.1% and 49.0%, respectively; p < 0.001) and low-density lipoprotein cholesterol (35.0% and 40.0%, respectively; p = 0.378). These differences remained, or even increased, after adjusting for changes in HIV-1 RNA and CD4+ cell levels, indicating an effect of the drugs on lipids over and above that which may be explained by suppression of HIV-1 infection. The increases in HDL-c were of the same order of magnitude as those seen with the use of the investigational HDL-c-increasing drugs. NVP-containing ART shows larger increases in HDL-c and decreases in TC:HDL-c ratio than an EFV-containing regimen. Based on these findings, protease-inhibitor-sparing regimens based on non-nucleoside reverse transcriptase inhibitor, particularly those containing NVP, may be expected to result in a reduced risk of coronary heart disease.